Bailard Inc. trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 119,758 shares of the company’s stock after selling 993 shares during the quarter. Bailard Inc.’s holdings in Johnson & Johnson were worth $20,487,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds also recently modified their holdings of JNJ. Steward Financial Group LLC bought a new position in shares of Johnson & Johnson during the fourth quarter worth about $34,000. Jackson Wealth Management LLC raised its position in shares of Johnson & Johnson by 1.7% during the third quarter. Jackson Wealth Management LLC now owns 16,959 shares of the company’s stock worth $40,000 after acquiring an additional 277 shares during the last quarter. Iron Horse Wealth Management LLC increased its holdings in Johnson & Johnson by 29.9% in the fourth quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company’s stock worth $45,000 after purchasing an additional 61 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its holdings in Johnson & Johnson by 290.7% in the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 293 shares of the company’s stock worth $47,000 after purchasing an additional 218 shares in the last quarter. Finally, Bell Investment Advisors Inc bought a new stake in Johnson & Johnson in the third quarter worth approximately $76,000. Institutional investors own 68.78% of the company’s stock.
JNJ stock traded down $1.02 during midday trading on Friday, hitting $176.85. The company’s stock had a trading volume of 7,732,163 shares, compared to its average volume of 7,745,147. The stock’s 50-day moving average price is $177.92 and its 200 day moving average price is $170.40. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The stock has a market cap of $465.36 billion, a price-to-earnings ratio of 23.83, a PEG ratio of 2.91 and a beta of 0.66.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 7th. Shareholders of record on Tuesday, May 24th will be given a $1.13 dividend. The ex-dividend date of this dividend is Monday, May 23rd. This represents a $4.52 annualized dividend and a yield of 2.56%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.06. Johnson & Johnson’s payout ratio is currently 57.14%.
In other Johnson & Johnson news, insider William Hait sold 29,699 shares of the business’s stock in a transaction on Thursday, April 21st. The stock was sold at an average price of $183.58, for a total value of $5,452,142.42. Following the sale, the insider now directly owns 80,236 shares in the company, valued at $14,729,724.88. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Thibaut Mongon sold 23,681 shares of the business’s stock in a transaction on Thursday, March 17th. The shares were sold at an average price of $176.25, for a total value of $4,173,776.25. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by insiders.
A number of equities research analysts have commented on JNJ shares. Bank of America started coverage on Johnson & Johnson in a research note on Wednesday, March 2nd. They issued a “neutral” rating for the company. Credit Suisse Group raised their price objective on Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a research note on Wednesday, April 20th. StockNews.com cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 30th. Citigroup raised their price objective on Johnson & Johnson from $203.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, April 20th. Finally, The Goldman Sachs Group raised their price objective on Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a research note on Tuesday, April 12th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Buy” and an average target price of $188.57.
About Johnson & Johnson (Get Rating)
Johnson & Johnson researches and develops, manufactures, and sells various products in the healthcare field worldwide. It operates in three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.